Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 3592.04 | 226 / 226 | 100% | 87.25 | 406 / 406 |
thymus | 100% | 4572.79 | 653 / 653 | 100% | 195.14 | 605 / 605 |
kidney | 100% | 4969.46 | 89 / 89 | 100% | 101.23 | 897 / 901 |
prostate | 100% | 3675.04 | 245 / 245 | 99% | 65.90 | 498 / 502 |
breast | 100% | 3335.28 | 459 / 459 | 99% | 163.59 | 1108 / 1118 |
skin | 99% | 3498.49 | 1790 / 1809 | 100% | 144.31 | 470 / 472 |
stomach | 100% | 2043.73 | 359 / 359 | 98% | 60.28 | 281 / 286 |
intestine | 100% | 2834.66 | 965 / 966 | 98% | 55.79 | 517 / 527 |
lung | 100% | 3938.82 | 576 / 578 | 98% | 77.84 | 1135 / 1155 |
uterus | 100% | 2616.51 | 170 / 170 | 98% | 76.86 | 449 / 459 |
ovary | 99% | 2014.19 | 179 / 180 | 98% | 74.89 | 423 / 430 |
adrenal gland | 100% | 7223.55 | 258 / 258 | 97% | 94.05 | 223 / 230 |
brain | 98% | 1693.69 | 2599 / 2642 | 97% | 95.59 | 685 / 705 |
bladder | 100% | 2259.43 | 21 / 21 | 94% | 63.08 | 472 / 504 |
pancreas | 94% | 1107.42 | 307 / 328 | 98% | 59.77 | 174 / 178 |
esophagus | 98% | 2297.09 | 1413 / 1445 | 93% | 56.89 | 171 / 183 |
eye | 0% | 0 | 0 / 0 | 100% | 333.79 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 151.12 | 29 / 29 |
spleen | 100% | 5352.01 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 115.01 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 45.86 | 1 / 1 |
adipose | 100% | 2935.94 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3688.78 | 1331 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 13175.11 | 924 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 2345.99 | 837 / 861 | 0% | 0 | 0 / 0 |
muscle | 86% | 1248.67 | 688 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051260 | Biological process | protein homooligomerization |
GO_0001525 | Biological process | angiogenesis |
GO_0012501 | Biological process | programmed cell death |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0042692 | Biological process | muscle cell differentiation |
GO_0070269 | Biological process | pyroptotic inflammatory response |
GO_0007155 | Biological process | cell adhesion |
GO_0034113 | Biological process | heterotypic cell-cell adhesion |
GO_0042246 | Biological process | tissue regeneration |
GO_0031640 | Biological process | killing of cells of another organism |
GO_0034145 | Biological process | positive regulation of toll-like receptor 4 signaling pathway |
GO_0002232 | Biological process | leukocyte chemotaxis involved in inflammatory response |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0007399 | Biological process | nervous system development |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0097060 | Cellular component | synaptic membrane |
GO_0140912 | Molecular function | membrane destabilizing activity |
GO_0098631 | Molecular function | cell adhesion mediator activity |
GO_0001530 | Molecular function | lipopolysaccharide binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NINJ1 |
Protein name | Ninjurin 1 Ninjurin-1 (hNINJ1) (Nerve injury-induced protein 1) [Cleaved into: Secreted ninjurin-1 (Soluble ninjurin-1)] |
Synonyms | |
Description | FUNCTION: [Ninjurin-1]: Effector of necroptotic and pyroptotic programmed cell death that mediates plasma membrane rupture (cytolysis) . Acts downstream of Gasdermin (GSDMA, GSDMB, GSDMC, GSDMD, or GSDME) or MLKL during pyroptosis or necroptosis, respectively: oligomerizes in response to death stimuli and promotes plasma membrane rupture by introducing hydrophilic faces of 2 alpha helices into the hydrophobic membrane, leading to release intracellular molecules named damage-associated molecular patterns (DAMPs) that propagate the inflammatory response . Acts as a regulator of Toll-like receptor 4 (TLR4) signaling triggered by lipopolysaccharide (LPS) during systemic inflammation; directly binds LPS . Involved in leukocyte migration during inflammation by promoting transendothelial migration of macrophages via homotypic binding (By similarity). Promotes the migration of monocytes across the brain endothelium to central nervous system inflammatory lesions . Also acts as a homophilic transmembrane adhesion molecule involved in various processes such as axonal growth, cell chemotaxis and angiogenesis . Promotes cell adhesion by mediating homophilic interactions via its extracellular N-terminal adhesion motif (N-NAM) . Involved in the progression of the inflammatory stress by promoting cell-to-cell interactions between immune cells and endothelial cells . Plays a role in nerve regeneration by promoting maturation of Schwann cells . Acts as a regulator of angiogenesis . Promotes the formation of new vessels by mediating the interaction between capillary pericyte cells and endothelial cells (By similarity). Promotes osteoclasts development by enhancing the survival of prefusion osteoclasts (By similarity). Also involved in striated muscle growth and differentiation (By similarity). .; FUNCTION: [Secreted ninjurin-1]: Secreted form generated by cleavage, which has chemotactic activity (By similarity). Acts as an anti-inflammatory mediator by promoting monocyte recruitment, thereby ameliorating atherosclerosis . . |
Accessions | Q92982 ENST00000375446.5 A0A0F6X1D7 |